[2nd CPMP of the European Union recommends the approval of pegylated liposomal doxorubicin in the treatment of metastatic breast cancer].
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002626:Chemistry, Pharmaceutical; D004317:Doxorubicin / Q000008:administration & dosage*; D017277:Drug Approval; D005062:European Union; D005079:Excipients; D005260:Female; D006801:Humans; D008081:Liposomes; D011092:Polyethylene Glycols
D000903:Antibiotics, Antineoplastic; D005079:Excipients; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin